LncRNA ZFAS1 inhibits triple-negative breast cancer by targeting STAT3

Sharma, Uttam; Barwal, Tushar Singh; Khandelwal, Akanksha; Malhotra, Akshay; Rana, Manjit Kaur; Rana, Anubhuti; Imyanitov, Evgeny N.; Vásquez, Karen M.; Jain, Aklank

doi:10.1016/j.biochi.2020.12.026

Cited by 34 publications

(18 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This negative correlation between STAT3 and specific lncRNAs indicated that lncRNAs could work as the negative regulators of STAT3 pathway. 103 , 104 , 105 It was reported that lncRNAs such as lncRNA‐p21, MEG3, and PTCSC3, as well as miRNAs such as miR‐548d‐3p and miR‐17 cluster family members, can directly target STAT3 and thereby regulate E‐cadherin expression. 103 , 106 , 107 , 108 , 109 , 110 …”

Section: Regulators Of the Stat3 Pathwaymentioning

confidence: 99%

STAT3 pathway in cancers: Past, present, and future

Wang

Man

Huo

et al. 2022

MedComm

View full text Add to dashboard Cite

Signal transducer and activator of transcription 3 (STAT3), a member of the STAT family, discovered in the cytoplasm of almost all types of mammalian cells, plays a significant role in biological functions. The duration of STAT3 activation in normal tissues is a transient event and is strictly regulated. However, in cancer tissues, STAT3 is activated in an aberrant manner and is induced by certain cytokines. The continuous activation of STAT3 regulates the expression of downstream proteins associated with the formation, progression, and metastasis of cancers. Thus, elucidating the mechanisms of STAT3 regulation and designing inhibitors targeting the STAT3 pathway are considered promising strategies for cancer treatment. This review aims to introduce the history, research advances, and prospects concerning the STAT3 pathway in cancer. We review the mechanisms of STAT3 pathway regulation and the consequent cancer hallmarks associated with tumor biology that are induced by the STAT3 pathway. Moreover, we summarize the emerging development of inhibitors that target the STAT3 pathway and novel drug delivery systems for delivering these inhibitors. The barriers against targeting the STAT3 pathway, the focus of future research on promising targets in the STAT3 pathway, and our perspective on the overall utility of STAT3 pathway inhibitors in cancer treatment are also discussed.

show abstract

Section: Regulators Of the Stat3 Pathwaymentioning

confidence: 99%

STAT3 pathway in cancers: Past, present, and future

Wang

Man

Huo

et al. 2022

MedComm

View full text Add to dashboard Cite

show abstract

“…Notably, with the advancement of high throughput next-generation sequencing methods, many lncRNAs have been explored to be used for cancer management ( 7 , 8 , 10 – 12 , 26 ). However, we could not find any studies demonstrating the comprehensive investigation of lncRNAs as diagnostic/prognostic biomarkers using blood samples of ESCC patients.…”

Section: Discussionmentioning

confidence: 99%

“…330404, Qiagen, Inc., Valencia, CA, USA) as described previously ( 26 ). We measured RNA concentration and quality using Nano"_xm_rop UV-Vis Spectrophotometer 2000cc (Thermo Fisher Scientific, CA, USA) followed by cDNA synthesis described previously ( 26 ). The qRT-PCR reactions were carried out as described previously ( 26 ).…”

Section: Methodsmentioning

confidence: 99%

“…We measured RNA concentration and quality using Nano"_xm_rop UV-Vis Spectrophotometer 2000cc (Thermo Fisher Scientific, CA, USA) followed by cDNA synthesis described previously ( 26 ). The qRT-PCR reactions were carried out as described previously ( 26 ). We normalized the expression of these lncRNAs using Glyceraldehyde-3-phosphate dehydrogenase ( GAPDH) as the reference gene and calculated the fold change with the 2 -ΔΔCT method.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Circulating Long Non-Coding RNAs LINC00324 and LOC100507053 as Potential Liquid Biopsy Markers for Esophageal Squamous Cell Carcinoma: A Pilot Study

et al. 2022

Self Cite

View full text Add to dashboard Cite

BackgroundDespite the availability of advanced technology to detect and treat esophageal squamous cell carcinoma (ESCC), the 5-year survival rate of ESCC patients is still meager. Recently, long non-coding RNAs (lncRNAs) have emerged as essential players in the diagnosis and prognosis of various cancers.ObjectiveThis pilot study focused on identifying circulating lncRNAs as liquid biopsy markers for the ESCC.MethodologyWe performed next-generation sequencing (NGS) to profile circulating lncRNAs in ESCC and healthy individuals’ blood samples. The expression of the top five upregulated and top five downregulated lncRNAs were validated through quantitative real-time PCR (qRT-PCR), including samples used for the NGS. Later, we explored the diagnostic/prognostic potential of lncRNAs and their impact on the clinicopathological parameters of patients. To unravel the molecular target and pathways of identified lncRNAs, we utilized various bioinformatics tools such as lncRnome, RAID v2.0, Starbase, miRDB, TargetScan, Gene Ontology, and KEGG pathways.ResultsThrough NGS profiling, we obtained 159 upregulated, 137 downregulated, and 188 neutral lncRNAs in ESCC blood samples compared to healthy individuals. Among dysregulated lncRNAs, we observed LINC00324 significantly upregulated (2.11-fold; p-value = 0.0032) and LOC100507053 significantly downregulated (2.22-fold; p-value = 0.0001) in ESCC patients. Furthermore, we found LINC00324 and LOC100507053 could discriminate ESCC cancer patients’ from non-cancer individuals with higher accuracy of Area Under the ROC Curve (AUC) = 0.627 and 0.668, respectively. The Kaplan-Meier and log-rank analysis revealed higher expression levels of LINC00324 and lower expression levels of LOC100507053 well correlated with the poor prognosis of ESCC patients with a Hazard ratio of LINC00324 = 2.48 (95% CI: 1.055 to 5.835) and Hazard ratio of LOC100507053 = 4.75 (95% CI: 2.098 to 10.76)]. Moreover, we also observed lncRNAs expression well correlated with the age (>50 years), gender (Female), alcohol, tobacco, and hot beverages consumers. Using bioinformatics tools, we saw miR-493-5p as the direct molecular target of LINC00324 and interacted with the MAPK signaling pathway in ESCC pathogenesis.ConclusionThis pilot study suggests that circulating LINC00324 and LOC100507053 can be used as a liquid biopsy marker of ESCC; however, multicentric studies are still warranted.

show abstract

“…Ren et al have shown that lncRNA PLACT1 promotes the malignant behaviour of pancreatic cancer through the NF-kappaB pathway, resulting in a worse prognosis [8]. Uttam et al showed that the lncRNA ZFAS1 is expressed at low levels in triple-negative breast cancer and can inhibit tumour progression [9]. This evidence supports that lncRNAs could serve as new molecular targets to improve the treatment of cancer.…”

Section: Introductionmentioning

confidence: 97%

Long noncoding RNA KB-1980E6.3 promotes breast cancer progression through the PI3K/AKT signalling pathway

Tang

Wang

et al. 2022

Preprint

View full text Add to dashboard Cite

This research aims to investigate the effect of lncRNA KB-1980E6.3 on the biological behaviour of breast cancer cells under normoxic conditions and the underlying molecular mechanism. The expression of KB-1980E6.3 in breast cancer tissues and cells was detected by RT–qPCR. The proliferation, migration and invasion of cells were evaluated by CCK-8, colony formation, scratch and Transwell assays; KB-1980E6.3-related xenograft models were established for in vivo studies. The protein expression of PI3K, p-PI3K, AKT and p-AKT was validated by western blotting analysis. The levels of KB-1980E6.3 are significantly upregulated in breast cancer tissues and cells and are related to the poor prognosis. Functional research both in vivo and in vitro revealed that the downregulation of KB-1980E6.3 significantly decreased cell proliferation, invasion and migration, while ectopic KB-1980E6.3 obviously promoted these biological phenotypes. In terms of the mechanism, KB-1980E6.3 is involved in the activation of the PI3K/AKT signalling pathway. Knockdown of KB-1980E6.3 reduces the expression of p-PI3K and p-AKT proteins, whereas KB-1980E6.3 overexpression shows the opposite result. The agonist 740Y-P and inhibitor LY294002 reversed the effect of KB-1980E6.3 knockdown and overexpression on the PI3K/AKT pathway in BC cells. KB-1980E6.3 promotes the proliferation, invasion and migration of breast cancer cells by activating PI3K/AKT signalling, which can be used as a potential target for breast cancer therapy.

show abstract

LncRNA ZFAS1 inhibits triple-negative breast cancer by targeting STAT3

Cited by 34 publications

References 41 publications

STAT3 pathway in cancers: Past, present, and future

STAT3 pathway in cancers: Past, present, and future

Circulating Long Non-Coding RNAs LINC00324 and LOC100507053 as Potential Liquid Biopsy Markers for Esophageal Squamous Cell Carcinoma: A Pilot Study

Long noncoding RNA KB-1980E6.3 promotes breast cancer progression through the PI3K/AKT signalling pathway

Contact Info

Product

Resources

About